BofA lowered the firm’s price target on Crispr Therapeutics (CRSP) to $79 from $80 and keeps a Buy rating on the shares. The company’s Q1 update focused on the potential acceleration for the Casgevy launch and proof-of-concept editing for CRISPR’s in vivo editing platform from initial data from CTX310, notes the analyst, who updated the firm’s model to reflect updated cash position, share count and expense trends.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRSP:
- Crispr Therapeutics AG: Strong Buy Rating Backed by Promising Clinical Data and Strategic Collaborations
- Crispr Therapeutics AG: Promising Trial Results and Strong Financial Position Support Buy Rating
- Crispr Therapeutics upgraded to Buy from Hold at Clear Street
- Crispr Therapeutics AG: Balancing Growth Potential with Profitability Challenges – Hold Rating
- Crispr Therapeutics reports Q1 EPS ($1.58), consensus ($1.28)
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue